VERU Stock Summary and Trading Ideas (Veru | NASDAQ:VERU)

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Veru trades on the NASDAQ stock market under the symbol VERU.

As of July 24, 2026, VERU stock price declined to $2.25 with 99,451 million shares trading.

VERU has a beta of 0.50, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.01 to the broad based SPY ETF.

VERU has a market cap of $36.11 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, VERU traded as high as $19.20 and as low as $2.05.

The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF, IWC.

VERU has underperformed the market in the last year with a price return of -62.5% while the SPY ETF gained +17.7%. VERU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.0% and -19.1%, respectively, while the SPY returned +3.8% and -2.1%, respectively.

VERU support price is $2.19 and resistance is $2.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.